1
Efficacy and Safety of Ultra Small Dose Decitabine for the Lower Risk MDS Patients With Transfusion Dependent
Condition(s):Myelodysplastic SyndromesLast Updated:February 7, 2017Unknown status
Decitabine: 493 Clinical Trials, Page 1 of 50
Hide Studies Not Open or Pending
2
Phase I:Decitabine by Hepatic Arterial Infusion(HAI) in Unresectable Liver Metastases Colorectal Cancer (CRC)
Condition(s):Liver Metastasis; Colorectal CancerLast Updated:October 27, 2017Completed
3
Ruxolitinib and Decitabine for High Risk Hematological Malignancies
Condition(s):Peripheral Blood Stem Cell TransplantationLast Updated:October 20, 2020Recruiting
4
Study of ASTX727 vs IV Decitabine in MDS, CMML, and AML
Condition(s):Myelodysplastic Syndromes; Chronic Myelomonocytic Leukemia; Acute Myeloid LeukemiaLast Updated:January 7, 2021Recruiting
5
Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults
Condition(s):Childhood Solid Tumor; Childhood Lymphoma; Relapsed Cancer; Refractory Cancer; Adult Solid Tumor; Adult LymphomaLast Updated:February 15, 2022Recruiting
6
Phase I, Dose Escalation Study of Decitabine
Condition(s):Leukemia, Lymphoblastic, Acute; Leukemia, Myeloid Acute; Hematopoetic MyelodysplasiaLast Updated:October 15, 2018Completed
7
Dose Finding Study of Post-BMT Decitabine Maintenance Treatment in Higher-risk MDS and MDS/AML
Condition(s):Myelodysplastic Syndrome; Acute Myeloid LeukemiaLast Updated:November 20, 2015Unknown status
8
5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies
Condition(s):Myelodysplastic Syndromes; MDS/MPN Crossover SyndromesLast Updated:August 20, 2021Recruiting
9
Efficacy and Safety of Low-dose Decitabine in Refractory Aplastic Anemia
Condition(s):Refractory Aplastic AnemiaLast Updated:May 12, 2021Recruiting
10
Randomized, Single-dose, Crossover Study of 4 Decitabine and Tetrahydrouridine (EPI01) Formulations in Healthy Subjects
Condition(s):HealthyLast Updated:May 9, 2019Completed